A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression

European Neuropsychopharmacology

Volumn 5, Issue 4, 1995, Pages 441-446

  Marttila, M ^a   Jaaskelainen J ^b   Jarvi R ^c   Romanov, M ^d   Miettinen, E ^e   Sorri, P ^f   Ahlfors, U ^g   Zivkov, M ^h  

^a Seinäojoki Hospital Clinic of General Hospital Psychiatry ^*  (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Mental Health Centre of Turku   (Finland)

^d Health Centre of Jyväskylä Cooperation   (Finland)

^e MIKKELI CENTRAL HOSPITAL   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g Hesperia Hospital   (Finland)

^h NV ORGANON   (Netherlands)

Author keywords

Doxepin; Major depression; Mirtazapine

Indexed keywords

DOXEPIN; MIRTAZAPINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DOXEPIN; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 0028792322     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-977X(95)80002-J     Document Type: Article

References (32)

1. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants
2. How recurrent and predictable is depressive illness?
3. Possible monoaminooxidase inhibitor-serotonin uptake inhibitor interactions: fluoxetine clinical data and preclinical findings
4. An inventory for measuring depression
5. Fluvoxamine
6. The safety profile of paroxetine
7. The diagnosis of depressive syndromes and the prediction of ECT response
8. Fatal toxicity of antidepressant drugs in overdose
9. A double-blind placebo-controlled study of mirtazapine in depressed outpatients
10. The effect of adrenergic drugs on serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vivo voltametry
11. The alpha-2 antagonist mirtazapine enhances serotonin transmission in vivo
12. The safety of antidepressants
13. Toleration and safety of sertraline: experience worldwide
14. The Global Assessment Scale: a procedure of measuring overall severity of psychiatric disturbance
15. Drug treatment of anxiety and depression
16. A rating scale for depression
17. A new depression scale designed to be sensitive to change
18. Selective serotonin reuptake inhibitors meta-analysis of discontinuation rates
19. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses
20. The Brief Psychiatric Scale
21. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of mirtazapine
22. Comparative tolerability profiles of the newer versus older antidepressants
23. Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks
24. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder
25. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability
26. Research Diagnostic Criteria: rationale and reliability
27. The serotonin syndrome
28. Mirtazapine is more effective than trazodone
29. The side effect profile and safety of fluoxetine
30. Mirtazapine vs amitriptyline: a 6-week randomised double-blind multicentre trial in hospitalised depressed patients